UY36617A - Proteínas de fusión inmunogénicas para el tratamiento del cáncer - Google Patents

Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Info

Publication number
UY36617A
UY36617A UY0001036617A UY36617A UY36617A UY 36617 A UY36617 A UY 36617A UY 0001036617 A UY0001036617 A UY 0001036617A UY 36617 A UY36617 A UY 36617A UY 36617 A UY36617 A UY 36617A
Authority
UY
Uruguay
Prior art keywords
fusion proteins
cancer treatment
immunogenic fusion
triggering
methods
Prior art date
Application number
UY0001036617A
Other languages
English (en)
Inventor
Peter M Lauer
William G Hanson
Dirk G Brockstedt
Meredith Lai Ling Leong
Fasso Marcella
Christopher Steven Rae
Charles G Drake
Original Assignee
Aduro Biotech Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Inc, Univ Johns Hopkins filed Critical Aduro Biotech Inc
Publication of UY36617A publication Critical patent/UY36617A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Abstract

En el presente documento se proporcionan composiciones y métodos para desencadenar una respuesta inmunitaria en un sujeto. En particular, la presente divulgación se dirige a proteínas de fusión inmunogénicas y a métodos para desencadenar una respuesta inmunitaria usando células hospedadoras que comprenden moléculas de ácido nucleico que codifican dichas proteínas de fusión.
UY0001036617A 2015-04-13 2016-04-12 Proteínas de fusión inmunogénicas para el tratamiento del cáncer UY36617A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146654P 2015-04-13 2015-04-13
US201562146626P 2015-04-13 2015-04-13
US201562263174P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
UY36617A true UY36617A (es) 2016-10-31

Family

ID=55808893

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036617A UY36617A (es) 2015-04-13 2016-04-12 Proteínas de fusión inmunogénicas para el tratamiento del cáncer

Country Status (11)

Country Link
US (2) US9808516B2 (es)
EP (1) EP3283100A2 (es)
JP (1) JP2018512165A (es)
CN (1) CN107980044A (es)
AU (1) AU2016247894A1 (es)
CA (1) CA2982543A1 (es)
HK (2) HK1250731A1 (es)
MA (1) MA44378A (es)
TW (1) TW201704267A (es)
UY (1) UY36617A (es)
WO (1) WO2016168214A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000137A1 (en) 2013-10-18 2017-10-06 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
MA44379A (fr) 2015-04-13 2019-01-23 Aduro Biotech Inc Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
CA2206343C (en) 1994-11-28 2009-04-07 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
EP1303299B1 (en) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
CA2496272A1 (en) 2002-08-20 2004-03-04 Millennium Pharmaceuticals, Inc. Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
CA2515298C (en) 2003-02-06 2014-04-08 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
EP1592441B1 (en) 2003-02-06 2012-04-11 Aduro Biotech Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
CA2529056C (en) 2003-06-17 2013-09-10 Mannkind Corporation Combinations of tumor-associated antigens in compositions for various types of cancers
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
PT1991263E (pt) 2006-03-01 2015-03-03 Aduro Biotech Listeria geneticamente modificada e métodos de uso da mesma
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
CA2818353A1 (en) 2010-11-17 2012-05-24 Aduro Biotech Methods and compositions for inducing an immune response to egfrviii
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SG11201502792TA (en) 2012-12-27 2015-05-28 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US9388243B2 (en) 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
AU2016247894A1 (en) 2015-04-13 2017-10-26 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
MA44379A (fr) 2015-04-13 2019-01-23 Aduro Biotech Inc Fusions variant iii du récepteur du facteur de croissance épidermique-mésothéline et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US20160324945A1 (en) 2016-11-10
WO2016168214A2 (en) 2016-10-20
CN107980044A (zh) 2018-05-01
MA44378A (fr) 2019-01-23
WO2016168214A3 (en) 2016-12-22
AU2016247894A1 (en) 2017-10-26
EP3283100A2 (en) 2018-02-21
JP2018512165A (ja) 2018-05-17
US9808516B2 (en) 2017-11-07
CA2982543A1 (en) 2016-10-20
HK1250731A1 (zh) 2019-01-11
US20180085446A1 (en) 2018-03-29
TW201704267A (zh) 2017-02-01
HK1250662A1 (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
CL2017002728A1 (es) Método para el tratamiento de cáncer
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112018012873A2 (pt) vacina de vírus zika
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
AR102527A1 (es) Vacunas terapéuticas para hpv16
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
PE20160528A1 (es) Anticuerpos
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221104